5467227e-26db-4241-9b21-0dd8ee39fcee
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- ADIPOGENESIS+0.300
- COAGULATION+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
- APOPTOSIS+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.300
- E2F_TARGETS-0.200
- MYC_TARGETS_V1-0.200
- SPERMATOGENESIS-0.200
- ANGIOGENESIS-0.100
- KRAS_SIGNALING_UP-0.100
- MITOTIC_SPINDLE-0.100
- UV_RESPONSE_DN-0.100
- ANDROGEN_RESPONSE+0.000
- KRAS_SIGNALING_DN+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_B3M5SGPA | low-grade glioma | — | 0.843 |
| 2 | BS_YCREDZTJ | low-grade glioma | — | 0.805 |
| 3 | 73A8C537-1F73-49FE-84BC-E9CC82D2A63E | — | — | 0.799 |
| 4 | BS_1NPD7PVG | Ganglioglioma | — | 0.788 |
| 5 | 580D2283-0AEE-42D8-AEDC-E5280DA56D81 | — | — | 0.786 |
| 6 | BS_C51RB0YR | low-grade glioma | — | 0.783 |
| 7 | TCGA-AC-A5EH-01A-11R-A28M-07 | — | C | 0.775 |
| 8 | BS_4Y6BCYK5 | pilocytic astrocytoma | — | 0.774 |
| 9 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.764 |
| 10 | BS_9BJARSX3 | pleomorphic xanthoastrocytoma(PXA) | — | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |